Graft-versus-host Disease Market Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast To 2023 Summary Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host's cells as foreign. GVHD can progress from mild to severe forms as either acute GVHD (aGVHD) or chronic GVHD (cGVHD). Both aGVHD and cGVHD commonly affect organs such as the skin, gastrointestinal (GI) tract, liver, oral mucosa, and eyes. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of aGVHD in the 6MM, from 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed incident cases in 2023, at an Annual Growth Rate (AGR) of 4.35% during the forecast period. Similarly, GlobalData epidemiologists forecast an increase in the diagnosed incident cases of cGVHD in the 6MM, from 7,359 diagnosed incident cases in 2013 to 10,485 diagnosed incident cases in 2023, at an AGR of 4.25% during the forecast period. Read Complete Report with TOC: http://www.radiantinsights.com/research/epicastreport-graft-versus-host-disease-epidemiology-forecast-to-2023 To forecast the diagnosed incident cases of aGVHD and cGVHD in the 6MM, GlobalData epidemiologists selected nationally-representative studies that provided the diagnosed incidence of aGVHD and cGVHD using the uniform validated diagnostic criteria and classification defined by the Center International Blood and Marrow Transplant Research standard grading system for aGVHD, and the standard criteria for cGVHD. In this analysis, GlobalData epidemiologists provided detailed, clinically relevant segmentations for the diagnosed aGVHD and cGVHD cases. Another strength of this analysis is that the same methodology was used across the 6MM, thereby allowing for meaningful global comparisons of the diagnosed incident GVHD cases. Scope - The Graft-Versus-Host Disease (GVHD) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for the diagnosed incidence of hematopoietic stem cell transplantations (HSCTs) (including first, multiple, and re-transplants), segmented by transplant type (autologous and allogeneic), and the diagnosed incident cases of GVHD in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). GlobalData epidemiologists also forecast the four-year diagnosed prevalent cases of acute GVHD (aGVHD) and the five-year diagnosed prevalent cases of chronic GVHD (cGVHD) in the 6MM. - The GVHD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM. Reasons to buy - Develop business strategies by understanding the trends shaping and driving the global GVHD market. - Quantify patient populations in the global GVHD market to improve product design, pricing, and launch plans. - Organize sales and marketing efforts by identifying the groups that present the best opportunities for GVHD therapeutics in each of the markets covered. - Identify the number of incident and prevalent aGVHD and cGVHD cases. Table Of Content: 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 7 Request Free Sample Of This Study @ http://www.radiantinsights.com/research/epicastreport-graft-versus-host-disease-epidemiology-forecast-to-2023#tabs-4 2 Introduction 8 2.1 Catalyst 8 2.2 Related Reports 9 2.3 Upcoming Reports 9 3 Epidemiology 10 3.1 Disease Background 10 3.2 Risk Factors and Comorbidities 11 3.3 Global Trends 13 3.4 Forecast Methodology 14 3.4.1 Sources Used 16 3.4.2 Sources Not Used 24 3.4.3 Forecast Assumptions and Methods 24 3.5 Epidemiological Forecast for GVHD (2013-2023) 30 3.5.1 Diagnosed Incident Cases of HSCTs 30 3.5.2 Diagnosed Incident Cases of Autologous HSCTs 32 3.5.3 Diagnosed Incident Cases of Allogeneic HSCTs 33 3.5.4 Diagnosed Incident Cases of aGVHD 35 3.5.5 Four-Year Diagnosed Prevalent Cases of aGVHD 37 3.5.6 Diagnosed Incident Cases of cGVHD 39 3.5.7 Five-Year Diagnosed Prevalent Cases of cGVHD 40 3.6 Discussion 42 3.6.1 Epidemiological Forecast Insight 42
3.6.2 Limitations of the Analysis 43 3.6.3 Strengths of the Analysis 44 4 Appendix 45 4.1 Bibliography 45 4.2 About the Authors 50 4.2.1 Epidemiologists 50 4.2.2 Reviewers 50 4.2.3 Intrim Director of Epidemiology 52 4.2.4 Global Director of Epidemiology (Through May 2014) 52 4.2.5 Global Head of Healthcare 53 4.3 About GlobalData 54 4.4 About EpiCast 54 4.5 Disclaimer 55 List of Tables Table 1: Risk Factors and Comorbidities for GVHD 12 Table 2: 6MM, Sources of HSCT, aGVHD, and cGVHD Data Used for the Forecast 16 Table 3: 6MM, Sources Not Used in the Epidemiological Analysis of GVHD 24 Table 4: 6MM, Diagnosed Incident Cases of HSCTs, Both Sexes, All Ages, N, 2013-2023 31 Table 5: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023 32 Table 6: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 20132023 34 Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare Table 7: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 36 Table 8: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 38 Table 9: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 39 Table 10: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 41 List of Figures Figure 1: Flow Chart of Derivation of aGVHD and cGVHD Patient Population in the 6MM 14 Figure 2: 6MM, Diagnosed Incident Cases of HSCTs , Both Sexes, All Ages, N, 2013-2023 31 Figure 3: 6MM, Diagnosed Incident Cases of Autologous HSCTs, Both Sexes, All Ages, N, 2013-2023 33
Figure 4: 6MM, Diagnosed Incident Cases of Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 35 Figure 5: 6MM, Diagnosed Incident Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, Both Sexes, All Ages, N, 2013-2023 37 Figure 6: 6MM, Four-Year Diagnosed Prevalent Cases of aGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, 2013-2023 38 Figure 7: 6MM, Diagnosed Incident Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 40 Figure 8: 6MM, Five-Year Diagnosed Prevalent Cases of cGVHD in Diagnosed Incident Cases of First Allogeneic HSCTs, All Ages, Both Sexes, N, 2013-2023 41 About Us Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of Ancillary services such as, research partnerships/ tie-ups and customized research solutions. Media Contact: Michelle Thoras Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Website: Radiant Insights Visit Our Blog: radiantri.blogspot.com